HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Puma Biotechnology (NASDAQ:PBYI) and maintained a $7 price target, as stated by analyst Edward White.
June 03, 2024 | 11:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Puma Biotechnology and maintained a $7 price target, indicating continued confidence in the company's stock.
The reiteration of a Buy rating and maintenance of a $7 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100